ALK and cancer: While no other malignancy fits this model quite as well as CML, there are similar resistance mutation phenomena in Gastrointestinal stromal tumour (GIST), Ph + acute lymphoblastic leukaemia (ALL), EGFR-mutant non small cell lung cancer (NSCLC), ALK-rearranged NSCLC, and other cancers.